Patiromer促进射血分数降低心衰合并高钾血症患者的RAS抑制剂和MRA治疗
DIAMOND研究导入期评估Patiromer辅助下HFrEF合并高钾血症或既往高钾血症患者RAS抑制剂/MRA优化情况。1038例完成导入期,878例(84.6%)随机化,160例(15.4%)导入失败。随机组中高钾血症患者目标RAS抑制剂使用从76.8%升至98.6%,MRA从35.9%升至98.6%;既往高钾血症患者RAS抑制剂从60.5%升至98.1%,MRA从15.6%升至98.7%。导入失败组也有改善。
要点
- Patiromer辅助下,HFrEF合并高钾血症患者RAS抑制剂和MRA使用显著增加。
- 84.6%患者达到随机化标准,实现≥50%推荐RAS抑制剂剂量、50 mg/d MRA和血钾正常。
- 即使导入失败组,RAS抑制剂和MRA使用也有提升。
核心结论
- 在HFrEF合并高钾血症或既往高钾血症且RAS抑制剂/MRA治疗不充分的患者中,Patiromer辅助的导入期内RAS抑制剂/MRA优化使用增加。
研究设计与样本
- DIAMOND研究导入期,患者接受≤12周Patiromer辅助的RAS抑制剂/MRA优化,以达到≥50%推荐RAS抑制剂剂量、50 mg/d MRA和血钾正常。
- 共1038例完成导入期,878例(84.6%)随机化,160例(15.4%)导入失败。
主要发现
- 随机组中,高钾血症患者目标RAS抑制剂使用从76.8%升至98.6%,MRA从35.9%升至98.6%。
- 随机组中,既往高钾血症患者目标RAS抑制剂使用从60.5%升至98.1%,MRA从15.6%升至98.7%。
- 导入失败组中,目标RAS抑制剂使用从52.5%升至70.6%,MRA从15.0%升至48.1%。
- 导入失败组中,高钾血症患者RAS抑制剂从51.5%升至64.7%,MRA从19.1%升至39.7%。
- 导入失败组中,既往高钾血症患者RAS抑制剂从53.3%升至75.0%,MRA从12.0%升至54.3%。
关键数值与推荐
- 随机化标准:≥50%推荐RAS抑制剂剂量、50 mg/d MRA和血钾正常。
- 进入导入期时,422例(40.7%)存在高钾血症,随机组与导入失败组频率相似(40.3% vs 42.5%;P=0.605)。
临床怎么用
- 对于HFrEF合并高钾血症或既往高钾血症且RAS抑制剂/MRA治疗不充分的患者,可考虑使用Patiromer辅助以促进RAS抑制剂和MRA的优化。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hyperkalemia (HK) is associated with suboptimal renin-angiotensin system (RAS) inhibitor and mineralocorticoid receptor antagonist (MRA) use in heart failure with reduced ejection fraction (HFrEF). OBJECTIVES: This study sought to assess characteristics and RAS inhibitor/MRA use in patients receiving patiromer during the DIAMOND (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure) run-in phase. METHODS: Patients with HFrEF and HK or past HK entered a run-in phase of ≤12 weeks with patiromer-facilitated RAS inhibitor/MRA optimization to achieve ≥50% recommended RAS inhibitor dose, 50 mg/d MRA, and normokalemia. Patients achieving these criteria (randomized group) were compared with the run-in failure group (patients not meeting the randomization criteria). RESULTS: Of 1,038 patients completing the run-in, 878 (84.6%) were randomized and 160 (15.4%) were run-in failures. Overall, 422 (40.7%) had HK entering run-in with a similar frequency in the randomized and run-in failure groups (40.3% vs 42.5%; P = 0.605). From start to the end of run-in, in the randomized group, an increase was observed in target RAS inhibitor and MRA use in patients with HK (RAS inhibitor: 76.8% to 98.6%; MRA: 35.9% to 98.6%) and past HK (RAS inhibitor: 60.5% to 98.1%; MRA: 15.6% to 98.7%). Despite not meeting the randomization criteria, an increase after run-in was observed in the run-in failure group in target RAS inhibitor (52.5% to 70.6%) and MRA use (15.0% to 48.1%). This increase was observed in patients with HK (RAS inhibitor: 51.5% to 64.7%; MRA: 19.1% to 39.7%) and past HK (RAS inhibitor: 53.3% to 75.0%; MRA: 12.0% to 54.3%). CONCLUSIONS: In patients with HFrEF and HK or past HK receiving suboptimal RAS inhibitor/MRA therapy, RAS inhibitor/MRA optimization increased during patiromer-facilitated run-in.
引用
- Pitt, Anker, Lund, et al. Patiromer Facilitates Angiotensin Inhibitor and Mineralocorticoid Antagonist Therapies in Patients With Heart Failure and Hyperkalemia. J Am Coll Cardiol. 2024. PMID: 39322323. doi:10.1016/j.jacc.2024.05.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。